Parker
Institute
Cancer
ends here
Parker is rewiring how breakthrough cancer immunotherapy treatments are discovered, developed, and delivered to patients.
Our Model
We bring together the world’s leading scientists, institutions, and industry partners to make sure promising cancer immunotherapy treatments move further, faster — from early investigation all the way to real-world patient impact.
Discoveries
Innovations
BioVentures
Discoveries
More Collaboration = More Progress
Parker Institute's network includes over a dozen centers and labs and hundreds of individual investigators relentlessly pursuing cancer immunotherapy's most promising science — not in silos, but together. Our long-term relationships encourage continuity and collaboration, and our early-career awards ensure a deep bench for the long haul.
Meet the Parker Institute Researchers
View directoryResearch Focus Areas
We define the frontiers and breakthroughs with the most potential, and create the conditions for researchers to explore them freely. Across our Focus Areas, Parker Institute scientists are making paradigm-shifting and practice-changing discoveries, resulting in a meaningful body of new research each year — with each finding bringing us closer to a future free from cancer.
Systems Cancer Immunology
Systems Cancer ImmunologyNeoantigen-Driven Targeting
Neoantigen-Driven TargetingCancer Vaccines
Cancer VaccinesIn Vivo Immune Engineering
In Vivo Immune Engineering
Twice a year, Parker Institute scientists and members of our broader community meet to share cutting-edge research and build long-term relationships.
Innovations
Keeping Discoveries on a Pathway to Patients
A fundamental challenge in cancer research is the gap between new findings and the funding needed to move beyond the lab. Parker Institute acts as a bridge. We collaborate with technology transfer and business development teams at each Center to help translate discoveries across the Parker Institute network into real licensing and new company outcomes. By working together to shepherd promising innovations, we help accelerate the development of breakthrough therapies to help patients faster.
600+ Inventions
and Counting
Since its founding, Parker Institute has yielded over 600 inventions, spanning novel screening techniques, engineering and armoring technologies, and machine learning applications to power the next wave of innovation. The most promising of these inventions have been licensed or optioned to companies equipped to see them through to their fullest potential.
Kelonia Theraputics licensed Parker Institute IP and recently sold to Eli Lilly for $3.25 billion.
Orbital Therapeutics licenses Parker Institute IP and was recently acquired by BMS for $1.5 billion.
Arsenal Biosciences utilizes 8 separate Next-Gen Cell Therapy technologies developed by Parker Institute investigators.
Kelonia Theraputics licensed Parker Institute IP and recently sold to Eli Lilly for $3.25 billion.
Orbital Therapeutics licenses Parker Institute IP and was recently acquired by BMS for $1.5 billion.
Arsenal Biosciences utilizes 8 separate Next-Gen Cell Therapy technologies developed by Parker Institute investigators.
BioVentures
Converting Innovations into Companies, and Cures
The next stage in our self-sustaining model is company formation. Our investment portfolio includes 14 companies, several of which were born out of the Parker Institute network and co-founded by Parker Institute-supported investigators. Several companies have advanced their therapies into clinical trials.
Revenue received from licensing or investment proceeds then circulates back into research — amplifying our impact over time, and ensuring the pipeline for research funding never runs dry.
Parker Institute recently convened a congressional briefing on Capitol Hill exploring the transformative potential of cancer vaccines.
Patients are the point
Our entire model is built around one important imperative: developing game-changing immunotherapy-based cancer treatments, and getting them to patients who need them.
